Editor-in-Chief of the Carlat Child Psychiatry Report, Dr. Joshua D. Feder, discusses the latest issue about depression in children and adolescents. The double issue features an expert interviews with Danella Hafeman, MD, PhD and Calvin Colarusso, MD.
Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. Does it work? Listen and find out!